Patents by Inventor Anatolijs Birmans

Anatolijs Birmans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8889902
    Abstract: Novel betaine salts of acetylsalicylic acid, namely 4-trimethylammoniobutanoate acetylsalicylic acid addition salt (gamma-butyrobetaine acetylsalicylate), L-carnitine acetylsalicylic acid addition salt and 3-(trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt. Use of meldonium acetylsalicylate as antiplatelet agent for treating various pathologies induced by platelet aggregation, anti-inflammatory and antihyperlipidemic agent.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: November 18, 2014
    Assignee: Tetra, SIA
    Inventors: Ivars Kalvins, Anatolijs Birmans, Maris Veveris, Antons Lebedevs, Anatolijs Misnovs
  • Publication number: 20120088742
    Abstract: Novel betaine salts of acetylsalicylic acid, namely 4-trimethylammoniobutanoate acetylsalicylic acid addition salt (gamma-butyrobetaine acetylsalicylate), L-carnitine acetylsalicylic acid addition salt and 3-(trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt. Use of meldonium acetylsalicylate as antiplatelet agent for treating various pathologies induced by platelet aggregation, anti-inflammatory and antihyperlipidemic agent.
    Type: Application
    Filed: June 21, 2010
    Publication date: April 12, 2012
    Applicant: Tetra, Sia
    Inventors: Ivars Kalvins, Anatolijs Birmans, Maris Veveris, Antons Lebedevs, Anatolijs Misnovs
  • Patent number: 7223797
    Abstract: New salts of Meldonium, the method of their preparation, and pharmaceutical formulation on their basis have been described. The general formula of these salts is X?(CH3)3N+NHCH2CH2COOH where X? is an acid anion selected from the group of pharmaceutically acceptable acids. Practically non-hygroscopic and/or increased thermal stability and/or lasting action Meldonium hydrogen salts of fumaric acid, phosphoric acid, oxalic acid, maleic acid, and pamoic acid as well as Meldonium orotate and galactarate are especially suitable. Novel pharmaceutical formulations containing non-hygroscopic and/or increased thermal stability and/or and/or lasting action 3-(2,2,2-trimethylhydrazinium) propionate salts for oral parenteral, rectal, and transdermal introduction are concurrently described.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: May 29, 2007
    Assignee: Joint Stock Company “Grindeks”
    Inventors: Ivars Kalvinsh, Anatolijs Birmans
  • Publication number: 20060264506
    Abstract: New salts of Meldonium, the method of their preparation, and pharmaceutical formulation on their basis have been described. The general formula of these salts is X?(CH3)3N+NHCH2CH2COOH where X? is an acid anion selected from the group of pharmaceutically acceptable acids. Practically non-hygroscopic and/or increased thermal stability and/or lasting action Meldonium hydrogen salts of fumaric acid, phosphoric acid, oxalic acid, maleic acid, and pamoic acid as well as Meldonium orotate and galactarate are especially suitable. Novel pharmaceutical formulations containing non-hygroscopic and/or increased thermal stability and/or and/or lasting action 3-(2,2,2-trimethylhydrazinium) propionate salts for oral parenteral, rectal, and transdermal introduction are concurrently described.
    Type: Application
    Filed: July 15, 2004
    Publication date: November 23, 2006
    Inventors: Ivars Kalvinsh, Anatolijs Birmans
  • Publication number: 20040242590
    Abstract: New medical use for gamma-butyrobetaine is disclosed. Also disclosed are pharmaceutical compositions, containing gamma-butyrobetaine or combination thereof with 3-(2,2,2-trimethylhydrazinium)propionate or sildenafil for oral, parenteral, subcutaneous, transdermal, topical, sublingual, intrauretral, intranasal or rectal application, useful for stimulation of sexual activity and potency in mammals. The disclosed compositions, when applied orally for 6 weeks to non-narcotized male rats substantially increase their sexual activity, decreasing the arousal time, increasing the number of copulations and resultativeness of mounting attempts. When applied by intracavernous or intravenous mute said pharmaceutical compositions increase intracorporeal pressure and duration of erection, as well as restore stimulation-induced reflectory erection in narcotized animals.
    Type: Application
    Filed: March 4, 2004
    Publication date: December 2, 2004
    Inventors: Ivars Kalvinsh, Maris Veveris, Anatolijs Birmans